SCHEMBL565184

SCHEMBL565184

CC(C)CN(Cc1cc(Cl)c2c(c1)OCCCO2)C(=O)C(C)CNCc1cccc2c1OCC2

nearest known ligand 0.71

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 5/20 0.71
MAPK8 P45983 1/20 0.35
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
MTNR1A P48039 1/20 0.33
ACKR3 P25106 1/20 0.33
ROCK2 O75116 1/20 0.30
ROCK1 Q13464 1/20 0.30
PIK3CA P42336 1/20 0.30
PIK3CB P42338 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10119922 1.00 PROKR2 (0.71) PROKR2MAPK8HTR2AHTR2CMTNR1A
SCHEMBL13284760 0.92 PROKR2 (0.61) PROKR2HTR2AHTR2CMTNR1AROCK2
SCHEMBL564206 0.92 PROKR2 (0.75) PROKR2MAPK8MTNR1AROCK2ROCK1
SCHEMBL565586 0.91 PROKR2 (0.70) PROKR2MAPK8MTNR1AACKR3
SCHEMBL565621 0.90 PROKR2 (0.72) PROKR2MAPK8HTR2AMTNR1AROCK2
SCHEMBL565414 0.89 PROKR2 (0.74) PROKR2MAPK8ACKR3NPC1RAB9A
SCHEMBL565438 0.89 PROKR2 (0.70) PROKR2MAPK8ACKR3
SCHEMBL565130 0.89 PROKR2 (0.73) PROKR2MAPK8MTNR1AACKR3NPC1
SCHEMBL564205 0.88 PROKR2 (0.70) PROKR2MAPK8MTNR1AACKR3ROCK2
SCHEMBL565569 0.88 PROKR2 (0.72) PROKR2MAPK8MTNR1AACKR3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof PROKR2, PROKR1, GIPR PROKR2 1/4885MAPK8 1270/4885HTR2A 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.